Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience

References

• Fullmer A, O’Brien S, Kantarjian H, et al. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs 2010;15:1–11.
   PubMed Web of Science ®Google Scholar
• Gatta G, Rossi S, Foschi R, et al. Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica 2013;98:744–752.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and2005: a report from the children's oncology group.J Clin Oncol 2012;30:1663–1669.
   Google Scholar
• Gokbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868–1876.
   PubMed Web of Science ®Google Scholar
• Daver N, O’Brien S. Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies. Curr Hematol Malig Rep 2013;8:123–131.
   PubMed Web of Science ®Google Scholar
• Nickel RS, Keller F, Bergsagel J, et al. Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma. Pediatr Blood Cancer 2014;61:810–814.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008;111:1827–1833.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101: 2788–2801.
   PubMed Web of Science ®Google Scholar
• Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995;85:2025–2037.
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532–543.
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia 2001;15: 208–216.
   PubMed Web of Science ®Google Scholar
• Larson RA. Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant 2009;15:11–16.
   PubMed Web of Science ®Google Scholar
• Lukenbill J, Advani AS. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep 2013;8:91–97.
   PubMed Web of Science ®Google Scholar
• Richardson DS, Johnson SA. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 1997;11:201–223.
   PubMed Web of Science ®Google Scholar
• Gottlieb AJ, Weinberg V, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood 1984;64: 267–274.
   PubMed Web of Science ®Google Scholar
• Narayanan S, Shami PJ. Treatment of acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol 2012;81:94–102.
   PubMed Web of Science ®Google Scholar
• Paciucci PA, Ohnuma T, Cuttner J, et al. Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 1983;43:3919–3922.
   PubMed Web of Science ®Google Scholar
• Errington F, Willmore E, Leontiou C, et al. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity. Cancer Chemother Pharmacol 2004;53:155–162.
   PubMed Web of Science ®Google Scholar
• Cao C, Han Y, Ren Y, et al. Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response. Cell Mol Immunol 2009;6:469–475.
   PubMed Web of Science ®Google Scholar
• Rosen PJ, Rankin C, Head DR, et al. A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. Leuk Res 2000;24:183–187.
   PubMed Web of Science ®Google Scholar
• Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010;376:2009–2017.
   PubMed Web of Science ®Google Scholar
• Patel S, Liedtke M, Ngo D, et al. A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leuk Lymphoma 2013;54: 2231–2235.
   PubMed Web of Science ®Google Scholar
• Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008;121:e387–396.
   PubMed Web of Science ®Google Scholar
• Escherich G, Zimmermann M, Janka-Schaub G; CoALL study group. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. Pediatr Blood Cancer 2013;60:254–257.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOGE2993. Blood 2005;106:3760–3767.
   Google Scholar
• Bassan R, Lerede T, Rambaldi A, et al. The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica 1995;80:280–291.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993;11:2002–2009.
   PubMed Web of Science ®Google Scholar
• Kaspers GL, Veerman AJ, Pieters R, et al. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia 1994;8:24–29.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Peng YM, Leigh S, et al. Disposition of mitoxantrone in cancer patients. Cancer Res 1985;45:1879–1884.
   PubMed Web of Science ®Google Scholar
• Weiss M, Maslak P, Feldman E, et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996;14:2480–2485.
   PubMed Web of Science ®Google Scholar